

## EPILEPSY

SATURDAY, MARCH 22 <sup>ND</sup> , 2025				
09:00-10:40	Epilepsy HALL B			
Chairs:	Lilach Goldstein, Israel; Ivan Rektor, Czech Republic			
09:00-09:50	Are the newest drugs for epilepsy, cenobamate and fenfluramine better than the older drugs?			
	<b>Capsule</b> : Drugs introduced to treat epilepsy in the 1990's and 2000's did not produce seizure freedom at greater rates than older drugs. Are the newest drugs better?			
09:00-09:10	Moderator: Maria Mazurkiewicz-Bełdzinska, Poland			
	Introduction and Pre-Debate Voting			
09:10-09:25	Yes: Michael Sperling, USA			
09:25-09:40	No: Zeljka Petelin Gadze, Croatia			
09:40-09:50	Discussion, Rebuttals and Post-Debate Voting			
09:50-10:40	Should we still use therapeutic drug monitoring when treating our patients with epilepsy?			
	Capsule: Does therapeutic drug monitoring really lead to better outcomes and seizure control or is management using clinical parameters adequate?			
09:50-10:00	Moderator: Ruta Mameniskiene, Lithuania			
	Introduction and Pre-Debate Voting			
10:00-10:15	Yes: Ilan Blatt, Israel			
10:15-10:30	No: Manjari Tripathi, India			
10:30-10:40	Discussion, Rebuttals and Post-Debate Voting			



## **EPILEPSY**

	SATURDAY, MARCH 22 <sup>ND</sup> , 2025				
13:10-14:50	Epilepsy (continued)	HALL B			
Chairs	Hadassa Goldberg-Stern, Israel; Nandan Yardi, India				
13:10-14:00	Should we use add-on therapy or substitution therapy for epilepsy when the first drug does not work?				
	Capsule: For most patients, is add-on and substitution of a new drug best when the first drug fails to control seizures? What is the evidence?				
13:10-13:20	Moderator: Elinor Ben Menachem, Sweden				
	Introduction and Pre-Debate Voting				
13:20-13:35	Add on: Alla Guekht, Russia				
13:35-13:50	Substitution: Andreas Schulze-Bonhage, Germany				
13:50-14:00	Discussion, Rebuttals and Post-Debate Voting				
14:00-14:50	Case studies. Michael Sperling, USA				
14:00-14:40	Case Discussion: intractable epilepsy and seizure clusters. Established and novel therapies, and administration method	ds, including trans-nasal.			
	Michael Sperling, USA & Faculty				
14:40-14:50	Discussion				



## **EPILEPSY**

	SATURDAY, MARCH 22 <sup>nd</sup> , 2025				
15:20-17:00	Epilepsy (continued)	HALL B			
Chairs	Andreja Bujan Kovač, Croatia; Tetyana Litovchenko, Ukraine				
15:20-16:10	0-16:10 Should we be targeting nuclei for deep brain stimulation other than the anterior thalamic nucleus for drug-resistant focal ep				
	Capsule: Stimulation of the anterior nucleus of the thalamus has been shown to reduce seizure frequency in a randomized controlled tria subocortical thalamicnuclei, including pulvinar and centromedian, are being now stimulated instead in clinical practice. Is this justified?				
15:20-15:30	Moderator: Irena Dolezalova, Czech Republic Introduction and Pre-Debate Voting				
15:30-15:45	Yes: Elinor Ben-Menachem, Sweden				
15:45-16:00	No: Martin Holtkamp, Germany				
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting				
16:10-17:00	Should we treat seizures that we see in the subclinical electrographic seizures in EEG in status epilepticus when	clinical seizures have stopped?			
	<b>Capsule</b> : It is common to see electrographic seizures after cessation of status epilepticus in the intensive care unit. Ca continued aggressive therapy? Is there evidence to support improved outcome with or without treatment?	an we justify treating these with			
16:10-16:20	Moderator: Vladimir Komarek, Czech Republic Introduction and Pre-Debate Voting				
16:20-16:35	Yes: <u>Ilan Blatt</u> , Israel				
16:35-16:50	No: Irena Dolezalova, Czech Republic				
16:50-17:00	Discussion, Rebuttals and Post-Debate Voting				